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Background: There is an urgent need for expanding and enhancing autism spectrum disorder (ASD) samples, in
order to better understand causes of ASD.
Methods: In a unique public-private partnership, 13 sites with extensive experience in both the assessment and diagnosis
of ASD embarked on an ambitious, 2-year program to collect samples for genetic and phenotypic research and begin
analyses on these samples. The program was called The Autism Simplex Collection (TASC). TASC sample collection began
in 2008 and was completed in 2010, and included nine sites from North America and four sites from Western Europe, as
well as a centralized Data Coordinating Center.
Results: Over 1,700 trios are part of this collection, with DNA from transformed cells now available through the National Institute
of Mental Health (NIMH). Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule-Generic
(ADOS-G) measures are available for all probands, as are standardized IQ measures, Vineland Adaptive Behavioral Scales
(VABS), the Social Responsiveness Scale (SRS), Peabody Picture Vocabulary Test (PPVT), and physical measures (height, weight,
and head circumference). At almost every site, additional phenotypic measures were collected, including the Broad Autism
Phenotype Questionnaire (BAPQ) and Repetitive Behavior Scale-Revised (RBS-R), as well as the non-word repetition scale,
Communication Checklist (Children’s or Adult), and Aberrant Behavior Checklist (ABC). Moreover, for nearly 1,000 trios, the
Autism Genome Project Consortium (AGP) has carried out Illumina 1 M SNP genotyping and called copy number variation
(CNV) in the samples, with data being made available through the National Institutes of Health (NIH). Whole exome
sequencing (WES) has been carried out in over 500 probands, together with ancestry matched controls, and this data is also
available through the NIH. Additional WES is being carried out by the Autism Sequencing Consortium (ASC), where the focus
is on sequencing complete trios. ASC sequencing for the first 1,000 samples (all from whole-blood DNA) is complete and
data will be released in 2014. Data is being made available through NIH databases (database of Genotypes and Phenotypes
(dbGaP) and National Database for Autism Research (NDAR)) with DNA released in Dist 11.0. Primary funding for the
collection, genotyping, sequencing and distribution of TASC samples was provided by Autism Speaks and the NIH, including
the National Institute of Mental Health (NIMH) and the National Human Genetics Research Institute (NHGRI).
Conclusions: TASC represents an important sample set that leverages expert sites. Similar approaches, leveraging expert
sites and ongoing studies, represent an important path towards further enhancing available ASD samples.* Correspondence: joseph.buxbaum@mssm.edu; lgallagh@tcd.ie
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Autism spectrum disorder (ASD) is a highly heritable
neurodevelopmental disorder characterized by funda-
mental deficits in social reciprocity and the presence of
restricted interests and/or repetitive behaviors [1]. ASD
is among the most prevalent of developmental disorders
with an estimated prevalence of about 1 in 100, with
males affected at a rate four times that of females [2]. A
substantial portion of the risk for ASD traces to genetic
variation, either inherited [1,3,4] or arising de novo
[5-11]. Through the strong support of families, advocacy
groups and international research initiatives, large col-
laborative networks have been formed to advance know-
ledge of genes associated with ASD, and in recent years,
these efforts have led to dramatic progress in the under-
standing of the genetics of ASD. Recent findings identify
examples of specific etiological mechanisms, while under-
scoring the highly complex nature of the genetic architec-
ture in ASD. To date, a specific genetic etiology can be
identified in up to 25% of individuals with ASD and include
single gene disorders (for example, Fragile X), known gen-
etic syndromes (for example, 22q11 deletion syndrome),
chromosomal anomalies, de novo and inherited copy num-
ber variation (CNV), indels, and single nucleotide vari-
ation (SNV) [12]. Intensive behavioral interventions can
have profoundly positive effects on the prognosis of aut-
ism (for example, see [13]), however morbidity and the
cost of ASD to society, families and individuals remains
high [14,15], reinforcing the need for earlier diagnosis and
ultimately, targeted treatment.
Further advances in the genetics of ASD will require
analysis of genetic variation at all levels, necessitating
the need to take advantage of new technology, including
that of massively parallel (high-throughput) sequencing,
and will require many thousands of samples to have ad-
equate power to identify rare variants associated with high
risk and more common variants associated with lower
risk. The Interagency Autism Coordinating Committee
(IACC) of the NIH, in its 2010 strategic plan, has called
for genetic analysis of some 20,000 unrelated families, a
number that is consistent with studies in other psychiatric
disorders such as schizophrenia (which also has a similar
prevalence and heritability to autism, see [16]). The IACC
recognized that in order to discover additional causes of
ASD to inform ‘prognosis and treatments and lead to the
prevention/preemption of the challenges and disabilities
of ASD’, the community would require such sample sizes.
In spite of the prevalence and burden of ASD, there
have not yet been sufficient large-scale initiatives to re-
cruit subjects to reach 20,000 unrelated families, and the
numbers of unrelated families available to researchers
through the National Institute of Mental Health (NIMH)
Center for Collaborative Genetic Studies on Mental
Disorders (CCGSMD) was still moderate in 2008. Tobegin to redress this, members of the Autism Genome
Project Consortium (AGP) made a proposal to Autism
Speaks to collect a large number of well-phenotyped trios
and to make them publically available through the existing
open process of the NIMH CCGSMD. The proposal
attempted to be modest in terms of costs because all par-
ticipating sites were already fully qualified on the relevant
instruments, had families in clinical and research studies
to turn to for participation, and all sites agreed to leverage
ongoing studies funded by parallel sources to carry out
the proposed sample collection at a fraction of the real
costs. After positive review at Autism Speaks, and a
critical parallel commitment by the NIMH to collect,
transform, and distribute biomaterials and data through
CCGSMD, The Autism Simplex Collection (TASC) was
awarded funds to ascertain 1,700 trios in this initiative.
As of today, the TASC samples are now available for
qualified researchers through the NIMH CCGSMD and
additional genotyping and whole exome sequencing (WES)
data is being made available for these samples on an
ongoing basis.
The Autism Genome Project Consortium
In 2004, through the support of the National Alliance for
Autism Research (NAAR), now Autism Speaks, the AGP
was launched as an international consortium of genetic re-
searchers from North America and Europe dedicated to
identifying genes that underlie susceptibility to ASD. The
goal of the AGP was to identify causes of ASD using mod-
ern genetic approaches and to then translate these find-
ings into better clinical practice. The members of the AGP
have joined together to reach these goals, recognizing that
an open collaborative structure would allow the field to
proceed with maximal efficiency. While a detailed descrip-
tion of the AGP is beyond the scope of the current manu-
script, it is important to highlight some recent successes
as they inter-relate with the goals of the TASC. The
AGP has consistently made use of state-of-the-art methods,
describing for the first time a genome-wide assessment of
CNV in ASD that included a first report of CNV at the
NRXN1 gene in ASD [7]. The AGP reported a large
genome-wide association study (GWAS) in ASD [17] and
has identified many CNVs that contribute to ASD risk [6].
This latter study showed that CNV in genes previously as-
sociated with intellectual disability (ID) are likely contrib-
uting to ASD risk and identified pathways that appear to
be implicated in ASD risk. The AGP collaborates with
other initiatives, carrying out genotyping where requested
(for example, see [18]) and providing all genotype data to
the Psychiatric Genetics Consortium (PGC; [19]) for
mega-analysis. Recently the AGP has completed genotyp-
ing another large sample (including much of TASC; Pinto
et al. in press) and has contributed over 1,000 TASC sam-
ples for WES. WES data from cases was generated and
Table 1 Target The Autism Simplex Collection (TASC)
sample contribution by site
Site Year 1 Year 2 Total
number
of trios
Portugal (AM Vicente and G Oliveira,
site co-PIs)
183 97 280
Mount Sinai (JD Buxbaum, site PI) 125 106 231
Ireland (L Gallagher, TASC PI and site PI) 100 102 202
Canada (P Szatmari, site PI) 100 85 185
Utah (H Coon, site PI) 100 85 185
Miami (M Cuccaro, site PI) 100 76 176
Vanderbilt Univ (JS Sutcliffe, site PI) 70 59 129
Frankfurt (CM Freitag and F Poustka site
co-PIs) and Heidelberg (SM Klauck, site PI)
59 50 109
AGRE (D Geschwind, site PI) 50 42 92
Indiana (JI Nurnberger, site PI) 40 34 74
Chicago (EH Cook, site PI) 20 30 50
CPEA (R Bernier, site PI) 5 4 9
Total 1,719
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National Human Genetics Research Institute (NHGRI),
through an American Recovery and Reinvestment Act
grant [3,8,20,21]. WES data from trios is now being gener-
ated by the ASC [22], again with support from the NIMH
and NHGRI.
The AGP thus represents a unique union of organi-
zations and research sites (over 50) that is comprised
of clinicians and researchers with recognized expert-
ise in ASD that work closely with local ASD groups
and families. Since 2003, AGP members have pub-
lished several hundred peer-reviewed papers on aut-
ism genetics research. The pooling of the extensive
scientific and clinical expertise from across the world
can serve to provide reliably characterized samples of
phenotype and genotype data to the scientific com-
munity. This is critical as large, reliable samples are cru-
cial for dissection of the genetic and genomic architecture
of ASD.
The Autism Simplex Collection (TASC)
In 2008, the AGP sought to provide an independent ASD
sample for gene discovery and phenotypic analyses, and
for replicating and extending findings from prior studies
carried out by the AGP and by additional research groups.
To this end, 13 sites within the AGP with extensive ex-
perience in the diagnosis and assessment of ASD made a
proposal that included recruitment of additional families
to the NIMH CCGSMD in a two-year period. Recruit-
ment would include in-depth expert phenotyping of all
families and biomaterials from all families.
Methods
Autism Speaks agreed to fund the collection of 1,700
samples, while the NIH agreed to assume the costs for
collecting, transforming and distributing the samples, as
well as warehousing all clinical information. Dr. Louise
Gallagher coordinated the recruitment with principle in-
vestigators at each site taking local responsibility (see
Table 1). Inclusion criteria included individuals aged be-
tween 3 and 21 years with a research diagnosis of autism/
ASD based on the Autism Diagnostic Interview-Revised
(ADI-R) and the Autism Diagnostic Observation Schedule
(ADOS) (administered by research reliable raters). Individ-
ual IQs were preferably greater than or equal to 35 based
on standardized testing and a full-scale or nonverbal men-
tal age of 18 months or greater. Only full parent-child
trios were included and the availability of an unaffected
sibling was not a requirement for inclusion. Individuals
with known medical or genetic causes of autism or a his-
tory consistent with Childhood Disintegrative Disorder
were excluded. Other exclusion criteria included: extreme
prematurity (< 1,000 grams or less than 32 weeks); prema-
turity with associated neurological complications; birthtrauma with associated early neo-natal complications;
significant brain injury; in utero exposure to medica-
tion known to be associated with autism, for example.
retinoic acid, sodium valproate. The Phenotype Proto-
col was developed and agreed by the members of the
AGP Phenotype Analytic Committee (Chair: Dr. Peter
Szatmari). Additionally, consultation with the Simon Sim-
plex Collection, which was also in a phase of phenotype
protocol development, allowed for cross-comparability of
some instruments. Core assessments carried out at all
sites included ADI-R [23] and ADOS-G [24] for the pro-
bands, as well as standardized IQ measures, Vineland
Adaptive Behavioral Scales (VABS) [25], Social Respon-
siveness Scale (SRS) [26], Peabody Picture Vocabulary
Test (PPVT) [27] and physical measures (height, weight,
and head circumference) (Table 2). In addition, at al-
most every site, additional phenotype measures were
assessed, including the Broad Autism Phenotype Question-
naire (BAPQ) [28] and Repetitive Behavior Scale-Revised
(RBS-R) [29], as well as the non-word repetition scale
(from the Comprehensive Test of Phonological Processing/
CTOPP-Domain V) [30], The Children’s Communication
Checklist-2 [31], Communication Checklist-Adult Version
[32], and Aberrant Behavior Checklist (ABC) [33] (Table 2).
Phenotypes were uploaded to a centralized database
in the Data Coordinating Center (DCC), which per-
formed point-of-entry data validation, facilitated cross-site
harmonization of clinical information, and provided com-
bined output data for analysis to ensure a common start-
ing point for analyses performed at different participating
sites.
Table 2 Phenotype measures in The Autism Simplex Collection (TASC) samples
Additional Measures AGRE Canada Chicago Washington Germany Ireland Miami Portugal Utah Vanderbilt Mount
Sinai
Indiana
ADI Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
ADOS Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Peabody Picture
Vocabulary Test (PPVT)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Nonword repetition scale No Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
Children’s communication
checklist-2
No Yes Yes No CCC-1 Yes No Yes Yes Yes Yes Yes
Communication
checklist-adult
No Yes Yes No No Yes No Yes Yes Yes Yes Yes
Standardized measure of IQ Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Vineland adaptive
behavior scales
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Social responsiveness
scale
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
BAPQ No Yes Yes Yes No Yes No Yes Yes Yes Yes Yes
Physical measures
(height, weight,
head circumference)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Repetitive behavior
scale-revised
Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
Aberrant behavior
checklist
No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
CCC-1, Children’s Communication Checklist-1.
Table 3 Summary data The Autism Simplex Collection
(TASC) sample
N %
Total sample
Individuals 5444
Families 1719
Children 1997
Male children 1643 82.4
Female children 354 17.8
Genetic data available
CNV data 2666 49.0
GWA data 2934 53.9
Whole exome data (not including
ongoing ASC data)
530 29.4 (cases only)
GWA-derived ancestry
European 2443 83.3
African 66 2.2
Latino 352 12.0
Asian 73 2.5
Classification
ADI (ASD1 or ASD2 [34] or autism) 1464
ADI (autism) (subset of above counts) 1339 91.5
ADOS (ASD or autism) 1262
ADOS (autism) (subset of above counts) 1008 79.9
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The consortium recruited over 90% of its target sample
in approximately two and a half years. The ambitious re-
cruitment was made feasible by capitalizing on sites with
active clinical and research programs, already utilizing
standardized, research-quality evaluation methods, and
by leveraging site-specific resources. The TASC collec-
tion includes a majority of European ancestry, but also
includes samples of more diverse ancestry. Summary sta-
tistics on ancestry, as well as ADI-R and ADOS-G diag-
noses, and available genetic data are shown Table 3.
Discussion
Genetic analyses of TASC samples
AGP members continue their work on ASD genetics
and have been making use of TASC samples to this end.
Over 400 TASC families are included in the two recent
AGP papers reporting on CNV and common SNPs in
ASD [6,17]. Additional TASC families are in the current
analysis in the follow-up AGP cohort (Pinto et al., in
press), such that to date, both genome-wide SNP data
and CNV calls have been generated for some 900 TASC
families. This data is being analyzed by the AGP and
shared with other sites, including the PGC [19] as well
as the database of Genotypes and Phenotypes (dbGaP)
and the National Database for Autism Research (NDAR).
Genotypes were managed and stored centrally in the
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there to the national databases. Called CNV are also avail-
able for TASC samples.
The TASC samples were also an important part of studies
sequencing over 1,000 ASD exomes using next-generation
sequencing. Five sites collaborated on this American
Recovery and Reinvestment Act (ARRA)-funded initia-
tive, where a premium was placed on making use of publi-
cally available samples that could be matched with control
samples using genome-wide SNP data. Using genome-
wide SNP data generated by the AGP from the approxi-
mately 950 TASC families, over 500 unrelated TASC ASD
subjects were selected for WES [3,8,20,21]. Sequen-
cing data from these families were released early 2012
via dbGaP. The same ARRA grant provided resources to
facilitate the release of TASC samples to additional re-
searchers through the NIMH CCGSMD. Most recently,
the ASC [22] has begun to sequence whole blood-derived
DNA from TASC samples, with support from the NIMH
and NHGRI. WES data from 1,000 samples (primarily in
the form of trios) will be released through dbGaP in 2014,
and data from additional TASC samples will be released
as the data become available.
TASC in the broader context
The goal identified by the IACC to examine 20,000 ASD
probands for genetic factors is consistent with studies
in other complex psychiatric disorders. As noted above,
both prevalence and heritability of schizophrenia are in
the same range as is seen for ASD [16]. In addition, like
ASD, schizophrenia risk includes CNV as a source of the
risk architecture [35,36]. The PGC has published a GWAS
with approximately 18,000 schizophrenia samples and
identified over 10 SNPs with very modest effect sizes [37],
with a larger study (with twice the number of affecteds)
now being completed. The PGC study in ASD, which in-
cludes all available SNP data in ASD (and virtually all
AGP and TASC data) accounts for over 5,000 samples.
Clearly it is not yet possible to identify multiple common
SNPs with very low effect sizes are part of the ASD risk,
as it is clear that common SNPs with odds ratios greater
than 1.3 can be excluded [38]. Even considering rareTable 4 Summary of available sample sets
Sample set Approximate number
of unrelated samples
Design
TASC 1,700 trios Simplex (no exclusi
ASD in the family
AGRE 1,700 families Primarily multiplex
Simons Simplex
Collection (SSC)
2,500 quads Simplex with unaffe
additional ASD in fi
NIMH CCGSMD 15,000 samples in current release
(with overlap with AGRE and TASC)
Multiple sources anvariation with major effect, large sample sizes are needed,
precisely because the variants are rare. In short, there is
every reason to think that the target of 20,000 proposed
by the IACC is required and that this sample size might
begin to achieve the associated goal crucial of the IACC,
which is to capture a significant proportion of the genetic
risk for ASD.
TASC shares similarities with other large-scale sample
collection. These include the Autism Genetic Resource
Exchange (AGRE) [39], a network originally funded by
Cure Autism Now (CAN) and now integrated into Autism
Speaks, and the Simons Simplex Collection [40], funded
by the Simons Foundation (see Table 4). In addition, the
NIMH has samples from prior collections, and efforts
are being made to collect additional samples. Collectively,
these important efforts can provide samples that approach
those in schizophrenia over the next several years and
provide greater power for broader analyses that will be re-
quired to fully comprehend the relationship between
genotype and phenotype.
Conclusions
There has been remarkable progress in ASD genetics in
the past several years, driven to no small degree by the
availability of large well-characterized samples. Relevant
genetic findings can now be made in over 25% of ASD
cases, using Fragile X testing, chromosome microarray
(CMA) and WES. Fragile X testing and CMA can iden-
tify genetic findings in more than 10% of cases. With
WES, studies in the past two years have shown that
deleterious de novo, recessive and X-linked mutations
are observed in some 12% of subjects, and WES identi-
fies small contributory CNV in some 7% of subjects
[3,4,8-11,41,42]. Moreover, recently identified mutations
and CNVs that are associated with high risk for ASD are
leading to a better understanding of ASD pathogenesis
and to model systems for ASD. Identification of high-
risk genetic variants can provide an etiological diagnosis
and opportunities for genetic counseling, an emerging
important aspect in ASD care [43]. In some examples of
monogenic forms of ASD, including Fragile X syndrome
and tuberous sclerosis, model systems have led clinicalWebsite
on for additional
www.agre.org
cted sib and no
rst degree relatives
https://sfari.org/resources/simons-simplex-collection
d designs https://www.nimhgenetics.org/
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tional nature of gene discovery in ASD research. Explain-
ing a large proportion of the genetic risk for ASD over the
next five years is an achievable goal, but will require larger
collections of well-characterized samples. The TASC re-
search group and the TASC samples represent a successful
collaboration and public-private partnership to enhance
the numbers of samples available through the NIMH
in less than three years. The phenotypic and genetic
data generated by the AGP and others provide unique
high value to this collection. Furthermore, the use of
these samples in many ongoing studies will continue to
add value to this collection. Similar approaches, lever-
aging expert sites and ongoing studies, represent an im-
portant path towards further enhancing the available ASD
sample set.
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